Trial Profile
Phase II Study of Cetuximab, Docetaxel and Cisplatin as First-line Treatment in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinomas - GORTEC2008-03 TPEx
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Tpex
- 23 Feb 2017 Status changed from active, no longer recruiting to completed.
- 16 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov
- 14 Feb 2011 New trial record